Tricares Raises €47M In A First Closing Of Its Series C Financing To Fund Further Development Of Minimally Invasive Treatment For Tricuspid Regurgitation
Tricares Raises €47M In A First Closing Of Its Series C Financing To Fund Further Development Of Minimally Invasive Treatment For Tricuspid Regurgitation
09/15/22, 11:05 AM
Location
parisMoney raised
€47 million
Industry
medical device
medical
biotechnology
health care
Round Type
series c
TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation
Company Info
Location
paris, ile de france, france
Additional Info
TRiCares is developing a transcatheter-based tricuspid valve replacement system aimed at addressing the need for a better treatment for this frequent and severe disease that avoids open heart surgery. Frederik Groenewegen, General Partner at 415 Capital, commented: “TRiCares is developing what we believe has the potential to become a best-in-class therapy option to restore quality of life for millions of patients suffering from tricuspid regurgitation.